Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.65
- Piotroski Score 4.00
- Grade Equal-Weight
- Symbol (CCCC)
- Company C4 Therapeutics, Inc.
- Price $5.70
- Changes Percentage (-3.22%)
- Change -$0.19
- Day Low $5.67
- Day High $6.07
- Year High $11.88
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.50
- High Stock Price Target $20.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.37
- Trailing P/E Ratio -1.97
- Forward P/E Ratio -1.97
- P/E Growth -1.97
- Net Income $-132,493,000
Income Statement
Quarterly
Annual
Latest News of CCCC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Analysts upgraded C4 Therapeutics' revenue forecasts, predicting a 3.1% decline in sales in 2024. Despite reduced losses and improved revenue outlook, the consensus price target fell 14%. The company ...
By Yahoo! Finance | 1 month ago -
C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?
The article discusses the potential of biotech penny stocks in 2024, focusing on C4 Therapeutics, Inc. as a promising investment. With a strong financial position and strategic partnerships, C4 Therap...
By Yahoo! Finance | 3 months ago -
CCCC Design & Consulting Group And Two More Top Dividend Stocks In China
China's market struggles with declining home prices and mixed economic signals, impacting investor sentiment. Dividend stocks like CCCC Design & Consulting Group offer potential stability and income i...
By Yahoo! Finance | 3 months ago
